Predictors and time trends in clopidogrel and proton pump inhibitor coprescription with low-dose acetylsalicylic acid

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 5, 2012, Pages 463-469

  Cea Soriano, Lucía ^a   Bueno, Héctor ^b   Johansson, Saga ^c,d   García Rodríguez, Luis A ^a  

^a Spanish Centre for Pharmacoepidemiologic Research ^*  (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Aspirin; Clopidogrel; Prescriptions; Proton pump inhibitors; Trends

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CHRONIC DISEASE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; TICLOPIDINE; TIME FACTORS;

EID: 84859974722     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3195     Document Type: Article

References (46)

1. WHO. WHO: The global burden of disease: 2004 update: World Health Organisation; 2008.
2. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37(2): 577-617.
3. Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 776S-814S.
4. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116(7): e148-e304.
5. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29(23): 2909-2945.
6. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494-502.
7. García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001; 52(5): 563-571.
8. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364(9431): 331-337.
9. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152(1): 1-9.
10. Hernández-Díaz S, García Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160(14): 2093-2099.
11. García Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158(1): 33-39.
12. García Rodríguez LA, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12(5): 570-576.
13. Nielsen GL, Sorensen HT, Mellemkjoer L, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids: a register-based cohort study. Am J Med 2001; 111(7): 541-545.
14. Thomopoulos KC, Mimidis KP, Theocharis GJ, Gatopoulou AG, Kartalis GN, Nikolopoulou VN. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: endoscopic findings, clinical management and outcome. World J Gastroenterol 2005; 11(9): 1365-1368.
15. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177(4): 347-351.
16. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118(18): 1894-1909.
17. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333(7571): 726.
18. Cea Soriano L, García Rodríguez LA. Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. Front Pharmacol 2010; 1: 126.
19. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation 2010; 122(24): 2619-2633.
20. Abraham NS, Hartman C, Castillo D, Richardson P, Smalley W. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gastroenterol 2008; 103(2): 323-332.
21. Lanas A, García Rodríguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102(3): 507-515.
22. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008; 103(10): 2465-2473.
23. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16(4): 393-401.
24. Stuart-Buttle CD, Read JD, Sanderson HF, Sutton YM. A language of health in action: Read Codes, classifications and groupings. Proc AMIA Annu Fall Symp 1996:75-79.
25. First Data Bank. MULTILEX for primary care. In 2010
26. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52(20): 1628-1636.
27. Ruigomez A, Martin-Merino E, Rodriguez LA. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). Pharmacoepidemiol Drug Saf 2010; 19(6): 579-585.
28. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25(2): 166-181.
29. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98(10): 946-952.
30. Buettner HJ, Mueller C, Gick M, et al. The impact of obesity on mortality in UA/non-ST-segment elevation myocardial infarction. Eur Heart J 2007; 28(14): 1694-1701.
31. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24(11): 987-1003.
32. Brosnan R, Newby LK. Acute coronary syndromes in patients with diabetes mellitus: diagnosis, prognosis, and current management strategies. Curr Cardiol Rep 2003; 5(4): 296-302.
33. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298(7): 765-775.
34. Heras M, Bueno H, Bardaji A, Fernandez-Ortiz A, Marti H, Marrugat J. Magnitude and consequences of undertreatment of high-risk patients with non-ST segment elevation acute coronary syndromes: insights from the DESCARTES Registry. Heart 2006; 92(11): 1571-1576.
35. Vonkeman HE, Fernandez RW, van de Laar MAFJ. Under-utilization of gastroprotective drugs in patients with NSAID-related ulcers. Int J Clin Pharmacol Ther 2007; 45(5): 281-288.
36. Van der Linden MW, Gaugris S, Kuipers EJ, Van den Bemt BJ, van Herk-Sukel MP, Herings RM. Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in the Netherlands. Curr Med Res Opin 2009; 25(1): 195-204.
37. Thiefin G, Borel T, Schwalm MS, Barthélemy P. Gastroprotection in patients at risk of gastrointestinal NSAID complications: results of a general practitioner based survey in France. Gut 2007; 56(Suppl 3): A229 (TUE-G-186).
38. Targownik LE, Al-Mamfud A. The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease. Aliment Pharmacol Ther 2006; 23(6): 743-750.
39. Helsper CW, Smeets HM, Numans ME, Hoes AW, De Wit NJ. Trends and determinants of adequate gastroprotection in chronic NSAID prescription. Gut 2007; 56(Suppl 3): A27 (OP-G-123).
40. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21(17): 1406-1432.
41. Budaj A, Yusuf S, Mehta SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002; 106(13): 1622-1626.
42. Collet JP, Himbet F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000; 76(2-3): 257-258.
43. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110(16): 2361-2367.
44. Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 2004; 62(7): 1187-1189.
45. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 546S-592S.
46. Tveit A. New international guidelines on antithrombotic therapy in atrial fibrillation. Tidsskrift for Den Norske Laegeforening 2009; 129(13): 1332-1335.